Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Nojomi, 2020
 
IRCT20180725040596N2
RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
50/50 inconclusive 94%
RECOVERY, 2020
 
NCT04381936
RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1616/3424 inconclusive 3%
Sekhavati, 2020 RCTlopinavir/ritonavirlopinavir/ritonavirCOVID 19 hospitalizedsome concern
56/55 inconclusive -46%
Sekhavati, 2020 RCTlopinavir/ritonavirhydroxychloroquineCOVID 19 hospitalizedsome concern
56/55 inconclusive -46%
SOLIDARITY (lopi/rito), 2020
 
NCT04315948
RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1399/1372 inconclusive 0%

COVID-19 mild to moderate meta-analysis

ELACOI (lopinavir/ritonavir), 2020
 
NCT04252885
RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
21/7 inconclusive

COVID-19 severe or critically meta-analysis

Cao B, 2020
 
ChiCTR2000029308
RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
99/100 suggested -26% 28%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).